(NASDAQ:RXST) NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company")(NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW),...
Related Questions
What potential financial impact could the class action lawsuit have on RxSight’s valuation and stock price?
What are the key filing and response deadlines related to the lawsuit, and how might they affect short‑term trading activity?
How might this legal development influence market sentiment toward RxSight compared to its peers in the eye‑surgery device sector?